OptiBiotix has announced a trading and commercial update for H1/21E, demonstrating continued progression of its two-stage strategy. Unaudited revenues of £1.074m represent a 44.3% increase over the comparable period H1/20A. This was driven by an increase in the number of revenue generating partnerships entered into over the past 12 months, accessing new regions and bringing new products to market. Despite the impact of COVID-19, the company has made strong progress with its second-generation por ....
09 Aug 2021
Cenkos: OptiBiotix Health Plc -- Trading and commercial update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: OptiBiotix Health Plc -- Trading and commercial update
OptiBiotix Health PLC (OPTI:LON) | 20.2 0 0.0% | Mkt Cap: 19.8m
- Published:
09 Aug 2021 -
Author:
Chris Donnellan -
Pages:
5
OptiBiotix has announced a trading and commercial update for H1/21E, demonstrating continued progression of its two-stage strategy. Unaudited revenues of £1.074m represent a 44.3% increase over the comparable period H1/20A. This was driven by an increase in the number of revenue generating partnerships entered into over the past 12 months, accessing new regions and bringing new products to market. Despite the impact of COVID-19, the company has made strong progress with its second-generation por ....